201 related articles for article (PubMed ID: 32637467)
1. Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice.
Arlt H; Mullarkey T; Hu D; Baron R; Ominsky MS; Mitlak B; Lanske B; Besschetnova T
Bone Rep; 2020 Dec; 13():100291. PubMed ID: 32637467
[TBL] [Abstract][Full Text] [Related]
2. One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.
Varela A; Chouinard L; Lesage E; Smith SY; Hattersley G
J Bone Miner Res; 2017 Jan; 32(1):24-33. PubMed ID: 27748532
[TBL] [Abstract][Full Text] [Related]
3. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis.
Besschetnova T; Brooks DJ; Hu D; Nagano K; Nustad J; Ominsky M; Mitlak B; Hattersley G; Bouxsein ML; Baron R; Lanske B
Bone; 2019 Jul; 124():148-157. PubMed ID: 31051317
[TBL] [Abstract][Full Text] [Related]
4. Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption.
Doyle N; Varela A; Haile S; Guldberg R; Kostenuik PJ; Ominsky MS; Smith SY; Hattersley G
Osteoporos Int; 2018 Mar; 29(3):685-697. PubMed ID: 29260289
[TBL] [Abstract][Full Text] [Related]
5. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption.
Chandler H; Lanske B; Varela A; Guillot M; Boyer M; Brown J; Pierce A; Ominsky M; Mitlak B; Baron R; Kostenuik P; Hattersley G
Bone; 2019 Mar; 120():148-155. PubMed ID: 30343166
[TBL] [Abstract][Full Text] [Related]
6. Abaloparatide, the second generation osteoanabolic drug: Molecular mechanisms underlying its advantages over the first-in-class teriparatide.
Bhattacharyya S; Pal S; Chattopadhyay N
Biochem Pharmacol; 2019 Aug; 166():185-191. PubMed ID: 31136739
[TBL] [Abstract][Full Text] [Related]
7. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
Dempster DW; Zhou H; Rao SD; Recknor C; Miller PD; Leder BZ; Annett M; Ominsky MS; Mitlak BH
J Bone Miner Res; 2021 Apr; 36(4):644-653. PubMed ID: 33434314
[TBL] [Abstract][Full Text] [Related]
8. Abaloparatide treatment increases bone formation, bone density and bone strength without increasing bone resorption in a rat model of hindlimb unloading.
Teguh DA; Nustad JL; Craven AE; Brooks DJ; Arlt H; Hu D; Baron R; Lanske B; Bouxsein ML
Bone; 2021 Mar; 144():115801. PubMed ID: 33338664
[TBL] [Abstract][Full Text] [Related]
9. Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β-arrestin recruitment than teriparatide.
Sahbani K; Cardozo CP; Bauman WA; Tawfeek HA
Physiol Rep; 2019 Oct; 7(19):e14225. PubMed ID: 31565870
[TBL] [Abstract][Full Text] [Related]
10. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
11. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
[TBL] [Abstract][Full Text] [Related]
12. Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: A comparison with teriparatide.
Makino A; Hasegawa T; Takagi H; Takahashi Y; Hase N; Amizuka N
Bone; 2021 Jan; 142():115651. PubMed ID: 32950699
[TBL] [Abstract][Full Text] [Related]
13. Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.
Le Henaff C; Ricarte F; Finnie B; He Z; Johnson J; Warshaw J; Kolupaeva V; Partridge NC
J Bone Miner Res; 2020 Apr; 35(4):714-724. PubMed ID: 31793033
[TBL] [Abstract][Full Text] [Related]
14. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
[TBL] [Abstract][Full Text] [Related]
15. Abaloparatide.
Gonnelli S; Caffarelli C
Clin Cases Miner Bone Metab; 2016; 13(2):106-109. PubMed ID: 27920805
[TBL] [Abstract][Full Text] [Related]
16. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
17. Abaloparatide is more potent than teriparatide in restoring bone mass and strength in type 1 diabetic male mice.
Marino S; Ozgurel SU; McAndrews K; Cregor M; Villaseñor A; Mamani-Huanca M; Barbas C; Gortazar A; Sato AY; Bellido T
Bone; 2024 Apr; 181():117042. PubMed ID: 38360197
[TBL] [Abstract][Full Text] [Related]
18. Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats.
Arlt H; Besschetnova T; Ominsky MS; Fredericks DC; Lanske B
JOR Spine; 2021 Mar; 4(1):e1132. PubMed ID: 33778406
[TBL] [Abstract][Full Text] [Related]
19. Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1-34).
Le Henaff C; Finnie B; Pacheco M; He Z; Johnson J; Partridge NC
JBMR Plus; 2023 Feb; 7(2):e10710. PubMed ID: 36751417
[TBL] [Abstract][Full Text] [Related]
20. Abaloparatide prevents immobilization-induced cortical but not trabecular bone loss after spinal cord injury.
Sahbani K; Pan J; Zaidi M; Cardozo CP; Bauman WA; Tawfeek HA
FASEB J; 2023 Jun; 37(6):e22984. PubMed ID: 37219516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
